Mounjaro vs Zepbound: Which Should You Take in 2026?

Readers of our Ozempic vs Wegovy guide will recognize the shape of this one immediately. Same playbook, played out on the tirzepatide side of the GLP-1 universe rather than the semaglutide side. Both are tirzepatide. Both are made by Eli Lilly. The differences are about FDA approvals, pricing, and insurance — not chemistry.

This guide explains everything that's actually different between Mounjaro and Zepbound, who should take which, and how the compounded tirzepatide market changes the math entirely in 2026.

Key Takeaways

• Same active ingredient (tirzepatide), same manufacturer (Eli Lilly).
• Different FDA approvals: type 2 diabetes is Mounjaro's. Zepbound holds weight management, and sleep apnea in obesity.
• Same doses: Both go from 2.5 mg to 15 mg weekly via the same titration schedule.
• Different list prices: Mounjaro ~$1,069/month, Zepbound ~$1,059/month — almost identical.
• Insurance coverage is much better for Mounjaro (diabetes patients) than for Zepbound (obesity patients).
• Compounded tirzepatide availability has been more volatile than semaglutide due to FDA shortage list changes.

Same Drug, Two Names

Eli Lilly developed tirzepatide, a dual GIP/GLP-1 receptor agonist — it acts on both. Two incretin pathways firing at once is the reason it outperforms single-pathway GLP-1 drugs such as semaglutide on weight loss. (For the head-to-head, see Semaglutide vs Tirzepatide.)

Lilly pursued two FDA approvals for the same molecule:

• Mounjaro: Approved May 2022 for type 2 diabetes
• Zepbound: November 2023 brought the weight-management approval; December 2024 added obstructive sleep apnea in adults who have obesity

The pharmacology is identical. Patients sometimes worry that the two products use different formulations or strengths. They don't — Lilly manufactures both at the same facility, and the only difference between a Mounjaro pen and a Zepbound vial is the labeling and packaging. (Zepbound is also available in a single-dose vial format that Mounjaro is not, which we'll get to.)

See the full molecule background in our tirzepatide drug guide.

What's Actually Different

1. FDA Indication

• Mounjaro: glycemic control, in adults who have type 2 diabetes mellitus, alongside diet and exercise.
• Zepbound: weight management over the long term. An adult qualifies at BMI ≥30, or at BMI ≥27 if a weight-related comorbidity comes with it. One more was added late in 2024: obstructive sleep apnea of moderate-to-severe grade, in adults who have obesity.

This matters for two reasons. First, your prescribing doctor must match the indication to your diagnosis. Second, insurance reimbursement is tied to the indication — covered for diabetes, often not covered for obesity.

2. Dosing — Identical

Both drugs use the exact same titration schedule:

Unlike Ozempic vs Wegovy (where the maintenance doses differ), Mounjaro and Zepbound max out at the same 15 mg dose. That makes the clinical decision easier: there's no "more powerful version" to chase.

3. Packaging and Format

• Mounjaro is sold exclusively in pre-filled single-dose pens.
• Zepbound is sold in pre-filled pens *and* in single-dose vials (introduced 2024 for cash-pay patients).

The vial format is meaningful. It allows Lilly to sell Zepbound directly to consumers at lower prices through LillyDirect — currently around $349/month for the lower doses (2.5 mg, 5 mg) for cash-pay patients. This was Lilly's response to the compounded tirzepatide market.

4. Pricing

Both brands run manufacturer savings programs that can reduce out-of-pocket costs significantly. Where a commercial plan declines to cover Zepbound, the Zepbound Savings Card can bring the monthly cost down to $25. The Mounjaro Savings Card has similar terms for diabetes patients.

5. Insurance Coverage

Same story as Ozempic vs Wegovy. Mounjaro is widely covered by insurance for type 2 diabetes patients. Zepbound coverage for obesity is patchy and often requires prior authorization with strict BMI and comorbidity documentation. Medicare does not cover Zepbound for weight loss (the recent OSA approval may change this for sleep apnea patients).

For a full breakdown of insurance options, see our Cost & Insurance pillar guide.

Compounded Tirzepatide: A Volatile Market

The FDA drug shortage list carried tirzepatide from 2022 until October 2024. This allowed 503A and 503B pharmacies to legally compound tirzepatide for patients whose doctors prescribed it. A robust telehealth industry sprang up, with providers offering compounded tirzepatide for $200–$400/month.

In October 2024, the FDA declared the shortage resolved. This triggered a legal challenge from compounding pharmacies, restraining orders, and a multi-month period of regulatory uncertainty. By 2026 the dust has mostly settled: 503B outsourcing facilities can still produce tirzepatide under specific exemptions, and 503A pharmacies can compound for individual patients with documented medical need (e.g. allergies to inactive ingredients in the brand product).

The practical consequence: compounded tirzepatide is still available through reputable telehealth providers, but the supply is more restricted than compounded semaglutide. Pricing has crept up from the 2024 lows, and not every provider that offered tirzepatide in 2024 still offers it in 2026.

Our best GLP-1 providers ranking flags which providers currently offer compounded tirzepatide and at what dose ranges. Notable options:

• CoreAge Rx — offers both compounded semaglutide and tirzepatide
• Henry Meds — tirzepatide available in select states
• Mochi Health — covers tirzepatide as part of their broader weight management program

For safety considerations, see our compounded semaglutide safety guide — the same principles apply to compounded tirzepatide.

Side Effects

One molecule, so one side effect profile — it does not vary between the two names:

• Common (>10%): fatigue, injection site reactions, and a run of gut effects — nausea, decreased appetite, diarrhea, constipation, vomiting, dyspepsia, abdominal pain
• Less common: hair loss, gallbladder disease, allergic reactions, and hypoglycemia (mostly in patients who also have diabetes)
• Rare but serious: acute kidney injury, pancreatitis, hypersensitivity reactions, severe gastrointestinal disease
• Boxed warning: rats developed thyroid C-cell tumors. It is contraindicated where MEN2 is present, and where medullary thyroid carcinoma appears in the patient's own history or the family's

In SURMOUNT-1, GI symptoms led to discontinuation in 14.7% of tirzepatide patients vs 2.6% of placebo. Slow titration is the most effective prevention strategy.

Who Should Choose Which?

Choose Mounjaro if you...

• Have type 2 diabetes (covered by insurance, on-label, lower out-of-pocket)
• Want the brand-name option and have insurance that covers diabetes drugs
• Need the cardiovascular and renal protective effects studied in SURPASS trials

Choose Zepbound if you...

• Don't have diabetes but qualify for weight management indication
• Have moderate-to-severe obstructive sleep apnea with obesity (FDA-approved indication as of late 2024)
• Can use the LillyDirect vial program for lower cash-pay pricing
• Have insurance that specifically covers Zepbound (or have access to the savings card)

Choose compounded tirzepatide if you...

• Have no insurance coverage for either brand
• Want the lowest out-of-pocket cost
• Are comfortable with the regulatory and supply uncertainty of the compounded market
• Use a verified telehealth provider sourcing from a 503B facility

Bottom Line

Mounjaro and Zepbound are functionally identical drugs with different labels for different patient populations. If you have diabetes, your doctor will prescribe Mounjaro and your insurance will probably cover it. If you don't have diabetes and are paying out-of-pocket, the practical decision is between Zepbound vials via LillyDirect (~$349–$499/month) and compounded tirzepatide via a trusted telehealth provider (~$199–$399/month).

For most weight-loss patients, the choice comes down to risk tolerance: brand-name Zepbound offers regulatory certainty and the strongest evidence base, while compounded tirzepatide offers a lower price with somewhat more legal and supply uncertainty.

For the broader picture on which GLP-1 to choose, read our Semaglutide vs Tirzepatide head-to-head. For help estimating your specific costs, use our savings calculator.